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Abstract
Background: Aromatase (CYP19A1) regulates estrogen biosynthesis. Polymorphisms in CYP19A1 have been related
to the pathogenesis of breast cancer (BC). Inhibition of aromatase with letrozole constitutes the best option for
treating estrogen-dependent BC in postmenopausal women. We evaluate a series of polymorphisms of CYP19A1
and their effect on response to neoadjuvant letrozole in early BC.
Methods: We analyzed 95 consecutive postmenopausal women with stage II-III ER/PgR [+] BC treated with
neoadjuvant letrozole. Response to treatment was measured by radiology at 4
th month by World Health
Organization (WHO) criteria. Three polymorphisms of CYP19A1, one in exon 7 (rs700519) and two in the 3’-UTR
region (rs10046 and rs4646) were evaluated on DNA obtained from peripheral blood.
Results: Thirty-five women (36.8%) achieved a radiological response to letrozole. The histopathological and
immunohistochemical parameters, including hormonal receptor status, were not associated with the response to
letrozole. Only the genetic variants (AC/AA) of the rs4646 polymorphism were associated with poor response to
letrozole (p = 0.03). Eighteen patients (18.9%) reported a progression of the disease. Those patients carrying the
genetic variants (AC/AA) of rs4646 presented a lower progression-free survival than the patients homozygous for
the reference variant (p = 0.0686). This effect was especially significant in the group of elderly patients not
operated after letrozole induction (p = 0.009).
Conclusions: Our study reveals that the rs4646 polymorphism identifies a subgroup of stage II-III ER/PgR [+] BC
patients with poor response to neoadjuvant letrozole and poor prognosis. Testing for the rs4646 polymorphism
could be a useful tool in order to orientate the treatment in elderly BC patients.
Background
After cessation of ovarian activity at postmenopause, the
aromatase [cytochrome P450 19 (CYP19);
OMIM:107910] from bones, adipose tissue and muscle,
becomes the key enzyme in estradiol and estrone bio-
synthesis through the aromatization of testosterone and
androstenedione respectively [1]. Aromatase is encoded
by CYP19A1 which maps at chromosome 15q21.1 and
has a complex structure with a region that contains 10
tissue-specific non-coding upstream exons with separate
promoters that regulate transcription in different cells
and tissues [2]. Elevated levels of aromatase expression
have been observed in breast tumors relative to normal
breast tissue [3], and alterations in aromatase expression
have been implicated in the pathogenesis of estrogen-
dependent diseases, including breast cancer (BC) [4,5].
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thirds of cases express estrogen (ER) and/or progester-
one receptors (PgR) [2,6,7], endocrine manipulation
being an effective treatment for these patients. Tamoxi-
fen, a selective ER modulator, has for decades been the
gold standard therapy in ER/PgR [+] BC patients [8].
However, in postmenopausal patients, aromatase inhibi-
tors like letrozole have consistently demonstrated to be
more effective than tamoxifen [9]. Letrozole is highly
specific for the aromatase enzyme and inhibits whole-
body aromatization of almost 99%, providing a highly
and essentially complete withdrawal of estrogen in post-
menopausal women [10].
Neoadjuvant hormonal therapy is a safety option for
postmenopausal women with large operable or locally
advanced hormone sensitive BC, increasing the possibili-
ties of breast-conserving surgery (BCS) [11]. In this con-
text, letrozole has shown to be more effective than
tamoxifen, obtaining higher response and BCS rates fol-
lowing 4 months of preoperative therapy [12,13]. How-
ever, less than 60% of patients will respond to this
optimal endocrine therapy [14]. To date, only the pre-
sence and intensity of hormonal receptors (ER/PgR) are
useful tools as predictive markers in clinical practice.
Identification of more accurate markers for more effi-
cient patient selection to exclude non-responsive cases
remains crucial.
Genetic polymorphisms in the CYP19A1 gene have
been associated with altered sex hormone levels in
serum and urine [15-17], providing an explanation for
an elevated risk for BC in relation to estrogen expo-
sure. For example, the tetranucleotide repeat poly-
morphism in intron 4 (TTTA)n has been associated
with BC risk in initial studies [18-22]. The polymorph-
ism rs10046 in the 3’ untranslated region (3’-UTR)
also showed inconsistent associations with BC risk
[23-26] and has also been related with tumor stage
[25], circulating sex hormone levels [15], HER2 status
and disease free and overall survival [27,28]. rs4646
has been reported to be associated with circulating
steroid hormone levels [17] and, as in rs10046, with
the HER2 status of the tumor [27]. Hence, it is biologi-
cally plausible that the polymorphisms in the CYP19A1
gene may be associated with the response to aromatase
inhibitors. Indeed, recently the rs4646 CYP19A1 poly-
morphism has been associated with letrozole efficacy
in advance disease [29]; however, no evidence between
CYP19A1 polymorphisms and therapeutic efficacy of
aromatase inhibitors in early stage BC has yet been
established.
In the present study, we perform a genetic analysis of
three CYP19A1 polymorphisms in a series of postmeno-
pausal endocrine-sensitive BC patients treated with
neoadjuvant letrozole and describe their association
both with radiological response at 4 months (RR4M) of
treatment and with progression free survival (PFS).
Methods
Patient selection and DNA samples
We identified a total of 153 postmenopausal patients
treated in our institution with letrozole as primary sys-
temic therapy for stage II - III BC between April 1999
and March 2008. Only those cases which met the fol-
lowing criteria were eligible for the study: 1) histological
diagnosis of invasive BC by tru-cut or biopsy; 2) positive
hormonal receptors status measured by immunohisto-
chemistry (> 10% ER and/or PgR); 3) preserved tumor
block; 4) bidimensionally measurable disease by mam-
mogram and/or breast ultrasound; 5) adequate radiolo-
gical follow-up at 4 months (± 14 days); 5) treatment
with letrozole (Femara: Novartis Pharma AG, Basel,
Switzerland) as neoadjuvant therapy by 2.5 mg/day for a
minimum of 4 months in the absence of progression or
side effects; and 6) patients able to provide a blood
sample.
Finally, 95 patients fulfilled all criteria, were contacted
by their physician (AGZ, ALC, ARS, JG, MAC, VG) and
agreed to participate on the study. All patients gave
their written consent for the use of their DNA for this
specific research proposal. In addition, this study was
reviewed and approved by the FIVO Science and Ethics
Committees.
Peripheral blood samples (7 ml) were obtained from
these patients and processed for DNA extraction at the
Laboratory of Molecular Biology.
Response to treatment at four months was done using
the WHO criteria: complete response (CR) required the
complete disappearance of all disease, partial response
(PR) was defined as a reduction of ≥ 50% in tumor
volume and stable disease (SD) was any reduction <
50% in tumor volume. The response evaluation was
done by an independent radiologist (JCD).
Pre-treatment study included patient characteristics,
menopausal status, disease history, histological grade
and diagnosis, evaluation of hormone receptor status,
HER2 and Ki67 status by immunohistochemical analy-
sis on core-cut biopsies, ECOG performance status
and tumor assessment. The clinical data were prospec-
tively reviewed and stored within a specific database.
Histological and immunohistochemical analysis
Core-cut biopsies were taken with a 14-guage needle
before treatment and fixed in neutral buffered formalin
for histological studies. The breast tumors were graded
according to the modified Bloom and Richardson score
on H&E-stained slides [30].
Four-micrometer sections from embedded blocks were
cut on poly-L-lysine-coated slides, and dewaxed,
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peroxide for 30 min. Immunoreactivity was enhanced
with antigen retrieval treatment by heating the slides in
a microwave oven for 10 min (700 W) in 10 mM
sodium citrate buffer pH 7, followed by cooling for 20
min at room temperature. Sections were blocked with
20% horse serum in phosphate-buffer saline (PBS) and
incubated with primary antibody for 1 h at room tem-
perature. The incubation time for the secondary anti-
body and avidin-biotin complexes was 30 min at room
temperature. Sections were extensively washed and the
immunoreactions developed using DAB (0.05% 3’3’ dia-
mino-benzidine in 0.1% hydrogen peroxide). Negative
controls included substitution of the primary antibody
by mouse ascites or PBS. Slides were counterstained in
Mayer hematoxylin, dehydrated, and mounted.
ER and PgR expression in primary tumor was immu-
nohistochemically evaluated using the anti-ER (clone
6F11) and anti-PgR (clone 1A6) antibodies (Novocastra
Laboratories, Newcastle upon Tyne, England) at a dilu-
tion of 1:40 and 1:30 respectively. Ki67 expression was
also determined using the anti-Ki67 (clone MIB1) anti-
body (Dako Corp., Carpinteria, CA) at a 1:50 dilution.
H E R 2p r o t e i ne x p r e s s i o nw as immunohistochemically
evaluated using the HercepTest Kit (Dako Corp., Car-
pinteria, CA) according to the manufacturer’sp r o t o c o l .
The scoring system was as follows: 0, tumors with no or
weak staining in less than 10% of the cells; +,t u m o r s
with a faint or barely perceptible membrane staining in
more than 10% of cells or with noncircumferential stain-
ing; ++, moderate circumferential membrane staining; +
++, strong circumferential membrane staining. Scores 0
and + were considered as negative; scores ++ and +++
were considered as positive for HER2 overexpression
[31].
DNA isolation
Genomic DNA used for genotyping studies was isolated
from peripheral blood mononucleated cells, previously
separated by centrifugation with Histopaque®-1077
(SIGMA-ALDRICH, LTD Irvine, UK), using the Ultra-
Clean DNA Blood Isolation Kit (MO BIO, Carlsbad,
CA, USA). DNA integrity was evaluated by the A260/
A280 absorbance ratio with a Nanodrop-1000 (Thermo
Scientific) spectrophotometer.
CYP19A1 Genotyping
The single nucleotide polymorphisms (SNPs) rs10046
(A/G) and rs4646 (C/A) located at the 3’-untranslated
region (3’-UTR) of CYP19A1, previously associated with
letrozole efficacy in advanced BC [29], and the rs700519
(C/T) in the first base of codon 264 (Arg
264Cys), related
with low levels of aromatase activity [32], were evalu-
ated. The rs700519 was analyzed by PCR amplification
and direct sequencing. Briefly, amplification was carried
out in a final volume of 25 μl containing 100 ng geno-
mic DNA, 0.3 μMo ff o r w a r d( 5 ’-CATGAAGTG-
TAGGGTC-TATGTAAT-3’) and reverse (5’-
GATCTTTACACACCTCTACACAGT-3’)p r i m e r s ,0 . 2
mM dNTPs (deoxyribonucleoside triphosphates), 2 mM
MgCl2, 1× _Buffer II (Applied Biosystems, New Jersey,
USA) and 1 unit AmpliTaq Gold (Applied Biosystems,
New Jersey, USA). PCR conditions were 94°C for 10
minutes; 35 cycles with denaturation at 94°C for 30 sec-
onds, annealing at 52°C for 30 seconds, and elongation
at 72°C for 30 seconds; and a final extension step at 72°
C for 10 minutes. PCR products were visualized on 1.5%
agarose gels containing ethidium bromide and after UV
radiation. Purified PCR products were then sequenced
using BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Warrington WA1 4SR, UK) and
electrophoresed on a ABI 3130xl Genetic Analyzer
(Applied Biosystems). Sequencing analysis was per-
formed with the Sequencing Analysis 5.2 Software
(Applied Biosystems).
Genotyping of the rs10046 and rs4646 polymorphisms
were carried out by allelic discrimination using specific
TaqMan SNP Genotyping Assays and following the
manufacturer’s instructions. In brief, 20 μl PCR reac-
tions were carried out containing 10.0 μlT a q M a nU n i -
versal PCR Master Mix (Applied Biosystems, New
Jersey, USA), 20.0 ng DNA template and 1.0 μLT a q -
Man SNP Genotyping Assays (Applied Biosystems, Fos-
ter City CA 94404). The references of selected assays
were: C_8234731_1 (rs10046) and C_8234730_1
(rs4646). All assays were performed in 96-well plates
including non-template controls. PCR reactions were
read on a 7500 Fast Real Time PCR System in end-
point mode using the Allelic Discrimination Sequence
Detector software (Applied Biosystems).
Statistical analysis
Statistical analysis was carried out using the SPSS statis-
tical software package (version 15.0.1, SPSS Inc., Chi-
cago, Illinois, USA). A total of 95 patients were included
in the analysis. Data on radiological response at the
fourth month of induction therapy, progression and sur-
vival status, immunohistochemical markers, histological
grade, stage and genotype were available for these
patients.
For the statistical analysis we used binary variables
reflecting the positivity status of the measures (yes or no)
as well as the genotypic status of each polymorphism
(homozygous reference or heterozygous/homozygous less
frequent). Association with histopathological parameters,
all categorical, was also assessed using a chi-square test to
determine homogeneity or linear trend for ordinal vari-
ables. The significance level was set at 5%.
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expected under Hardy-Weinberg equilibrium (HWE)
were assessed by c
2 (p > 0.05) tests [33].
To study the impact of the biological factors on progres-
sion-free survival (PFS), the Kaplan-Meier proportional
risk test (Log Rank) was used [34,35]. PFS was defined as
the time interval from the start of treatment to local or
distant disease progression. Those patients that reported
disease progression during the follow-up were considered
as censored, being the data of confirmation of this pro-
gression considered in the calculation of PFS. Univariate
predictors of PFS were entered into a Cox proportional
hazards model using stepwise selection to identify the
independent predictors of poor outcome, a confidence
interval (CI) of 95% was also considered [36].
Results
Patient and tumor characteristics
Ninety-five stage II-III ER/PgR-positive BC in postme-
nopausal women treated with letrozole as neoadjuvant
therapy were analyzed. The median age of the series was
78.3 years (range: 61.7-89.8). The histopathological and
clinical characteristics of the series are summarized in
Table 1. As shown, 67 patients presented infiltrating
ductal carcinoma (IDC), 16 infiltrating lobular carci-
noma (ILC) and the remaining 12 cases corresponded to
9 mucinous carcinomas, 2 tubular carcinomas and one
medullar carcinoma. The histological grade was available
in only 52 of the IDC due to sample limitations. Most of
the cases were stage IIa BC (68.4%), the majority of
cases having a T2 tumor (80%). All tumors expressed
HR (ER or PgR or both). Considering the whole HR
expression for each patient we distinguished two groups
of cases: those having low level HR (expressing HR in ≤
40% of tumor cells) and those with a high HR expres-
sion (> 40% of cells). Ten cases were classified in the
first group (10.5%). HER2 and Ki67 expression was also
evaluated, 32 cases were HER2 ++/+++ (33.7%) and 32
out of 73 cases analyzed expressed Ki67 (44.4%).
The median treatment period with letrozole as neoad-
juvant therapy was 10.23 months (range: 3.53-85).
Response to treatment was evaluated by radiological
means (mammogram or ultrasound) at four months of
letrozole administration using WHO criteria [37]. A
total of 34 partial responses (PR) and one complete
response (CR) where achieved, and were classified as
responders for the analysis. Hence, the overall radiologi-
cal response rate at 4 months (RR4M) was 36.8%. On
the contrary, 55 women remained with stable disease
(SD) and 5 developed progression disease (PD), these all
being considered as non-responders.
Table 1 Clinical and pathological characteristics of the
patients.
Parameter n (%)
Histological diagnosis*
IDC 67 (70.5)
ILC 16 (16.8)
Others 12 (12.6)
Histological grade
I 29 (55.8)
II 19 (36.5)
III 4 (7.7)
Tumor size (T)
T2 76 (80.0)
T3-T4 19 (20.0)
Lymph node involvement (N)
N0 76 (80.0)
N1-2 19 (20.0)
Stage
IIa 65 (68.4)
IIb 20 (21.1)
IIIa-IIIb 10 (10.5)
ER
Negative 5 (5.3)
10-40% 8 (8.4)
40-70% 25 (26.3)
> 70% 57 (60.0)
PgR
Negative 28 (29.5)
10-40% 18 (18.9)
40-70% 24 (25.3)
> 70% 25 (26.3)
HR**
≤ 40% 10 (10.5)
> 40% 85 (89.5)
HER2
Negative 39 (41.1)
+ 24 (25.3)
++ 22 (23.2)
+++ 10 (10.5)
Ki67
Negative 40 (55.6)
Positive 32 (44.4)
Response to letrozole
Non responders 60 (63.2)
Responders 35 (36.8)
Progression status
No progression 77 (81.1)
Progression 18 (18.9)
Garcia-Casado et al. BMC Cancer 2010, 10:36
http://www.biomedcentral.com/1471-2407/10/36
Page 4 of 11CYP19A1 polymorphism analysis
A total of three single nucleotide polymorphisms (SNPs)
were evaluated: one located in exon 7 (rs700519) and
two in the 3’-UTR region of CYP19A1 (rs10046 and
rs4646). Polymorphism references, genotypes, gene and
chromosome locations, and frequency distribution of
observed genotypes in the series are shown in Table 2.
In addition, values for Hardy-Weinberg (HW) [33] equi-
librium were estimated for each polymorphism and are
also listed in Table 2. Both rs10046 and rs4646 were in
HW equilibrium; however, for rs700519 this calculation
was not possible as no genetic variant (CT, TT) was
observed in any of the analyzed cases.
Analysis between RR4M and clinical, pathological and
genotypic parameters
No statistically significant association was found
between RR4M and the clinical and pathological para-
meters (Table 3). However, an overrepresentation of the
genetic variants (AC/AA) of the rs4646 polymorphism
was observed in the non-responder group (48.3%) com-
pared with the responders (25.7%) (p = 0.03) (Table 3).
Clinical, pathological, genotypic parameters and
progression free survival (PFS)
The median follow-up of the series was of 40.6 months
(range: 4.3-113.8 months). A total of 18 patients (18.9%)
reported disease progression during this period (Table
1). Among the analyzed parameters, IIIa-IIIb stages and
the non response to letrozole induction therapy were
significantly associated with shorter PFS (Table 4; Addi-
tional file 1: Supplemental Table S1; Fig. 1). Interest-
ingly, those patients carrying the genetic variants (AC/
AA) of rs4646 presented a worse PFS than the patients
homozygous for the reference variant (Table 4; Addi-
tional file 1: Supplemental Table S1; Fig. 2). Multivariate
analysis showed that lymph node involvement [Hazard
Ratio (HR) = 4.3 (1.7-11); p = 0.002] and RR4M [HR =
11 (1.5-83); p = 0.012] constituted independent prognos-
tic factors for PFS.
Clinical, pathological, genotypic parameters and PFS
according to the surgery status
Sixty-five out of the 95 patients (68%) underwent surgery
after letrozole induction therapy and no association was
observed between the progression status and surgery
(Table 1). In fact, 20% of non-surgery cases progressed,
while 18.5% of the surgery group experienced progression
events (p = 0.861). In addition, no significant differences
in terms of PFS were observed between the non-surgery
(74.5%) and surgery (60.4%) groups (p = 0.600). However,
when we compared clinical, pathological and genetic
parameters between the two groups of patients according
to surgery status, we observed that 77% of patients of the
non-surgery group were over the median age, compared
with 37% of the patients from the surgery group (p =
0.00032). Moreover, rs4646 variant (AC/AA) was overre-
presented in the non-surgery group (57%) in contrast to
the surgery group (32%) (p = 0.024).
Univariate analysis performed for PFS for each group
of patients revealed that in the non-surgery group,
RR4M and r4646 where associated with a worse prog-
nosis (Table 5; Additional file 2: Supplemental Table
S2). Indeed, the 6 patients who progressed were geneti-
cally characterized by the variant rs4646 (AC/AA) (Fig.
3A). However, in the multivariate analysis only the poly-
morphism rs4646 emerged as an independent prognostic
factor although it did not reach statistical significance (p
= 0.191).
Table 2 CYP19A1 polymorphisms and genotype frequencies
db-SNP id Genotype n (%) p* Gene location Chromosome position**
rs700519 CC 89 (100) - Exon 7 (codon 264) 49.295.260
CT 0 (0)
TT 0 (0)
rs10046 AA 23 (24.2) 0.127 3’UTR 49.290.278
AG 57 (60.0)
GG 15 (15.8)
rs4646 CC 57 (60.0) 0.397 3’UTR 49.290.136
AC 30 (31.6)
AA 8 (8.4)
*p > 0.05 is consistent with the Hardy-Weinberg equilibrium; ** Sequence of reference NT_010194.16.
Table 1: Clinical and pathological characteristics of the
patients. (Continued)
Surgery status
No surgery 30 (32.0)
Surgery 65 (68.0)
*IDC, Infiltrating ductal carcinoma; ILC, Infiltrating lobular carcinoma; Others
(Mucinous, tubular and medullar carcinomas).
**Hormonal status was considered as ≤ 40% when either estrogen and
progesterone receptors were ≤ 40%, and as > 40% when at least one of the
receptors were > 40%.
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tion, only Ki67 expression and RR4M were associated
with worse PFS (Table 5; Additional file 2: Supplemental
T a b l eS 2 ) ,a l t h o u g hn o n eo ft h e s ev a r i a b l e sw e r ei n d e -
pendent indicators of poor outcome. Contrary to that
observed in the non-surgery group, no association of the
rs4646 variants with PFS was observed (Fig. 3B).
Discussion
We describe a relationship between the genetic variants
(AC/AA) of the rs4646 polymorphism of CYP19A1 and
a poor response to neoadjuvant treatment with letrozole
in postmenopausal women with ER/PgR [+] BC. The
radiological response was measured at the 4
th month of
letrozole induction, the observed response rate being
36.8%, similar to the radiological response reported in
the P024 trial [12].
At genetic level, mutations in the aromatase gene may
lead to a functionally less sensitive aromatase phenotype.
Although mutations in the CYP19A1 gene can be gener-
ated in vitro, to date no somatic mutation has been
found in clinical samples [38]. However, several genetic
polymorphisms of CYP19A1 have been reported so far,
although the possible functional significance of most of
these remains undefined. In the case of BC, population-
based studies of common CYP19A1 polymorphisms
have generated inconsistent results with regard to their
possible association with sex hormone levels, cancer
risk, HER2 status or survival [15,19,21,27,28]. No asso-
ciation between the HER2 or hormonal status of either
rs10046 or rs4646 was observed in our series.
Whether aromatase inhibitor agents interact with the
different CY19A1 genotypes has not so far been clearly
established. Only three previous studies have attempted
to demonstrate the effect of certain polymorphisms in
CYP19A1 on the efficacy of aromatase inhibitors. In the
first, Fasching et al., in a series of patients treated with
hormonal therapy for more than 2 years, did not observe
significant differences between the rs700519, rs10046 and
rs4646 polymorphisms with therapy. Unfortunately, the
type of antihormonal therapy was not recorded for this
analysis [27]. In the second study, a population-based
and in vitro study, Ma et al. revealed reductions in the
functional activity of aromatase for four phenotypes
resulting from non-synonymous changes [rs700519
(Arg
264Cys), rs28757184 (Thr
201Met), rs2236722
(Trp
39Arg), and rs56658716 (Met
364Thr)] [32]. These
authors found that levels or aromatase enzyme activity
decreased dramatically for the Thr
364, and also observed
Table 3 Association of clinical, pathological and
genotypic parameters with radiological response at 4
th
month of letrozole administration.
Parameters Responders
(%)
Non-responders
(%)
p
Age (years)
≤ 78.3 19 (54.3) 29 (48.3) 0.576
> 78.3 16 (45.7) 31 (51.7)
Histological diagnosis
IDC 25 (71.4) 42 (70.0) 0.843
ILC 5 (14.3) 11 (18.3)
Others 5 (14.3) 7 (7.4)
Histological grade
I 13 (61.9) 16 (51.6) 0.606
II 6 (28.6) 13 (41.9)
III 2 (9.5) 2 (6.5)
Tumor size (T)
T2 31 (88.6) 45 (75.0) 0.111
T3-T4 4 (11.4) 15 (25.0)
Lymph node involvement
(N)
NO 28 (80.0) 48 (80.0) 1.000
N1-2 7 (20.0) 12 (20.0)
Stage 0.546
IIa 26 (74.3) 39 (65.5)
IIb 7 (20.0) 13 (21.7)
IIIa-IIIb 2 (5.7) 8 (13.3)
ER
≤ 40% 3 (8.6) 10 (16.7) 0.268
> 40% 32 (91.4) 50 (83.3)
PgR
≤ 40% 15 (42.9) 31 (51.7) 0.407
> 40% 20 (57.1) 29 (48.3)
HR
≤ 40% 2 (5.7) 8 (13.3) 0.243
> 40% 33 (94.3) 52 (86.7)
HER2
0, + 21 (60.0) 42 (70.0) 0.320
++, +++ 14 (40.0) 18 (30.0)
Ki67
Negative 15 (55.6) 25 (55.6) 1.000
Positive 12 (44.4) 20 (44.4)
rs10046
GG 6 (17.1) 9 (15.0) 0.782
AG/AA 29 (82.9) 15 (85.0)
rs4646
CC 26 (74.3) 31 (51.7) 0.030
AC/AA 9 (25.7) 29 (48.3)
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264 allozyme activity. They also
demonstrated that the mechanism by which non-synon-
ymous SNPs affect the enzymatic activity is a conse-
quence of an alteration in the enzyme protein level [32].
In the same study, these authors reported that these var-
iants had no significant differences in their affinity to the
aromatase inhibitors letrozole and exemestane [32].
Interestingly, the polymorphism rs700519 has also been
reported as a prognostic factor in a Chinese study, mainly
in a subgroup of premenopausal women [28], but not in
the Caucasian population [27]. In addition, it is impor-
tant to note the differences between these two popula-
tions regarding the minor allele frequency of rs700519,
being only 3.2% for the Caucasian population (1,257
patients) [27], in comparison with 15.1% in the Asian
Cohort (1,136 patients) [28]. In our series, the genetic
variants of this polymorphism were underrepresented
and not found in any of the cases.
The third study evaluated the efficacy of treatment
with letrozole in advanced hormone receptor-positive
BC patients with respect to two polymorphisms located
at the 3’-UTR (rs10046 and rs4646) and one in intron 2
[rs727479 (G/T)] of the CYP19A1 [29]. The authors
found that genetic variants of rs4646 were associated
with a greater efficacy of letrozole in terms of time to
progression. Hence, patients with the variant genotype
(AC/AA) had a three times greater time to progression
than the patients with the reference genotype (CC).
Furthermore, these authors reported that the frequency
of the variant alleles for rs4646 was significantly higher
in the responder (61%) than in the non-responder group
of patients (40%) [29]. These observations clearly differ
from those reported in our series, the genotypic variants
of rs4646 being more frequently represented in the non-
responder group to letrozole after 4 months of induc-
tion therapy (48% vs. 26%). In this regard, there are two
Figure 1 Kaplan Meier plot showing the progression-free survival with regard the radiological response to letrozole at 4
th month
(RR4M) of the induction therapy.
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these two studies. First, and independently of the disease
stage, are the criteria for patient selection. Whereas in
our series the patients were treated with letrozole as a
first line, in the study of Colomer et al. the patients had
progressed from a previous treatment with tamoxifen
[29]. It is well established that tamoxifen metabolism is
influenced by the number of mutant alleles of the gene
encoding cytochrome P450 2D6 (CYP2D6), because this
enzyme affects the levels of endoxifen, the active tamox-
ifen metabolite. Thus, for patients who are wild type for
CYP2D6, the 5-year disease-free survival outcomes are
similar to or perhaps even superior with tamoxifen than
with aromatase inhibitors [39]. Therefore, previous
treatment with tamoxifen could have genetically selected
a population of patients more sensitive to letrozole. Sec-
ondly, in our study we used constitutive DNA obtained
from peripheral blood for the genetic analysis, whereas
Colomer et al. performed the genetic study on DNA
o b t a i n e df r o mt h ef i x e da n dp a r a f f i n - e m b e d d e dt u m o r s
[29]. The polymorphism studies performed on tumor
samples are subject to genetic alterations that can affect
the chromosomal region of the gene under study. In
this way, CYP19A1 is located in the 21.2 region of the
long arm of chromosome 15 (15q21.2) [40], and this
region has been reported to be a frequent target of alle-
lic imbalance in advanced breast carcinomas [41], and
which could affect the frequency distribution of the alle-
lic variants.
From our series, 65 women underwent surgery after
letrozole induction, being age the only difference
observed between the operated and non-operated
patients. In fact 77% of patients within the non-surgery
group were over 78.3 years. We have demonstrated that
g e n e t i cv a r i a n t so fr s 4 6 4 6h a v ep r o g n o s t i cv a l u e ,e s p e -
cially in this group of patients. Indeed, the 6 women
w h op r o g r e s s e dw i t h i nt h eg r o u po fn o n - s u r g e r y
patients were genetically characterized by the variant
rs4646 (AC/AA). In this elderly group of patients the
decision for undergoing surgery is not always easy and
very often both the patient and the clinician opt for a
local control of the tumor maintaining the treatment
with letrozole. Hence, in this group of patients, in which
the tumor is not removed, is where the rs4646 poly-
morphism identifies the women who progressed, indi-
cating, and despite the small number the cases included
Figure 2 Kaplan Meier plot showing the progression-free survival with regard the genetic variants of rs4646 in the global series.
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Page 8 of 11in our series, that women with the rs4646 (AC/AA) gen-
otype could benefit from another therapeutic approach.
The regulatory interactions between the ER, growth
factor receptors and other kinase signalling pathways
could also determine the response to endocrine therapy.
In the adjuvant setting, several studies suggest that
patients overexpressing HER2 may derive relatively less
benefit from endocrine therapy [38]. In the P024 trial,
ER [+] tumors that were also EGFR and/or HER2 [+]
responded significantly better to letrozole than to
tamoxifen (88% vs 21% respectively, P = 0.0004) [13].
The IMPACT study, that confronted tamoxifen with
anastrozole, or the preoperative combination of both,
observed a similar effect in favour of anastrozole for
HER2 [+] tumors (Odds Ratio 58% vs. 22%), although
not reaching statistical significance [42]. In our series, as
in both randomized trials, no differences in activity were
observed relating to HER2 expression among the
patients receiving letrozole.
Biological studies of tissues obtained during neoadju-
vant therapy have thrown a different perspective on this
issue. Short-term estrogen deprivation leads to profound
changes in transcriptional profiles, and these changes
can be used as predictive tools. Tumor expression of the
proliferation antigen Ki67 after 2 weeks of endocrine
treatment (tamoxifen or anastrozole) predicts for clinical
response and recurrence-free survival [42]. However,
among cases on anastrozole, only 7% did not present a
reduction in the Ki67 expression at 2 weeks. In many
Table 4 Association of clinical, pathological and
genotypic parameters with progression free survival
(PFS).
Parameters n Events %PFS p
Tumor size
T2 76 12 62.6 0.089
T3-T4 19 6 59.3
Lymph node involvement
N0 76 10 57.31 0.0011
N1-N2 19 8 44.7
Stage
IIa 65 8 58.2 0.0232
IIb 20 6 65.1
IIIa-IIIb 10 4 42.3
RR4M
Responders 35 1 96.7 0.0033
Non-responders 60 17 45.6
rs10046
GG 18 3 80.0 0.967
AG/AA 80 15 81.3
rs4646
CC 57 7 85.7 0.0686
AC/AA 38 11 50.9
Figure 3 Kaplan Meier plot showing the progression-free survival with regard the genetic variants of rs4646 in the no surgery (A) and
surgery group of patients (B).
Table 5 Association of clinical and genotypic parameters
with progression free survival (PFS) according to surgery
status.
No surgery Surgery
Parameters n Events %
PFS
p n Events %
PFS
p
Ki67
Negative 17 5 66.9 0.686 23 1 50.0 0.023
Positive 5 1 80.0 27 8 69.6
RR4M
Responders 10 0 100 0.041 25 1 95.2 0.030
Non-
responders
20 6 58.8 40 11 47.8
rs4646
CC 13 0 100 0.009 44 7 81.5 0.790
AC/AA 17 6 44.1 21 5 59.0
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Page 9 of 11cases, this reduction in the tumor proliferation rate is
only modest and could not be sufficient to determine a
resistance to the treatment. As expected, early tumor
changes are not limited to proliferation markers, but to
other genes directly regulated by ER, including the aro-
matase itself [43]. Other, currently ongoing, approaches
have used gene expression profiling techniques able to
predict response to endocrine therapy, but the results
obtained so far are inconsistent [43]. In our series,
expression of proliferating marker Ki67 constituted a
factor of poor prognosis in the group of patients under-
going surgery following letrozole induction therapy, sug-
gesting that this marker could identify tumors with a
more aggressive behavior.
Conclusion
We have found that genetic variants of the polymorph-
ism rs4646 in the 3’-UTR of CYP19A1 are associated to
poor response to letrozole after 4 months induction
therapy and to poor outcome of elderly patients without
surgery after letrozole administration in postmenopausal
women with ER/PgR [+] BC. Although our study would
suggest that analysis of rs4646 could improve the clini-
cal management of these patients by facilitating a more
individualized therapy, further studies based on larger
series are necessary to confirm these findings.
List of abbreviations
3’-UTR: 3’-untranslated region; CYP19A1: aromatase
gene; BC: breast cancer; BCS: breast conserving surgery;
CR: complete response; DAB: diamino-benzidine; ER:
estrogen recetor; HWE: Hardy-Weinberg equilibrium;
IDC: infiltrating ductal carcinoma; ILC: infiltrating lobu-
lar carcinoma; PR: partial response; PBS: phosphate-buf-
fer saline; PgR: progesterone receptor; PD: progression
disease; PFS: progression free survival; RR4M: radiologi-
cal response at 4 months; SNPs: single nucleotide poly-
morphisms; SD: stable disease; WHO: World Health
Organization.
Additional file 1: Table S1. Association of clinical, pathological and
genotypic parameters with progression free survival (PFS). This table
shows the associations of the clinicopathological and genetic parameters
with PFS that have not been statistically significant.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
36-S1.DOC]
Additional file 2: Table S2. Association of clinical, histopathological and
genotypic parameters with progression free survival (PFS) according to
surgery status. This table shows the associations of the
clinicopathological and genetic parameters with PFS that have not been
statistically significant according to surgery status.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
36-S2.DOC]
Acknowledgements
We thank Maria Garcia Flores, Tania Mazcuñan and Laura Martinez for their
technical assistance.
This study has been financed by grants GV0A6/256 from the Conselleria
d’Empresa Universitat i Ciència of the Generalitat Valenciana (JALG) and
SOLTI 06/01 (ALLC).
Author details
1Laboratory of Molecular Biology, Fundación Instituto Valenciano de
Oncología, Valencia, Spain.
2Department of Medical Oncology, Fundación
Instituto Valenciano de Oncología, Valencia, Spain.
3Department of Medical
Oncology, Hospital Arnau de Villanova, Lleida, Spain.
4Department of
Pathology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
5Department of Pathology, University of Valencia, Spain.
6Department of
Radiology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
7Department of Surgery, Fundación Instituto Valenciano de Oncología,
Valencia, Spain.
Authors’ contributions
ZGC carried out the molecular genetic studies, participated in the genetic
analysis and drafted the manuscript. AGZ reviewed the clinical records of
the patients included in the study and drafted the manuscript. AFS
performed the genetic analysis. ALlC, ARS, JG, MAC and VG treated most of
the patients included in the study and updated the clinical follow-up. AC,
SA and ALlB carried out the histopathological and immunohistochemical
analysis. JCD performed the radiological evaluation of the study. JC and CVA
performed the trucut biopsies and informed to the patients about the study.
JALG conceived of the study, performed the statistical analysis and
participated in its design and coordination and helped to draft the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 3 September 2009
Accepted: 9 February 2010 Published: 9 February 2010
References
1. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM,
Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD, et al:
Aromatase cytochrome P450, the enzyme responsible for estrogen
biosynthesis. Endocr Rev 1994, 15(3):342-355.
2. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, Martin R,
Utsunomiya H, Thung S, Gurates B, et al: Regulation of aromatase
expression in estrogen-responsive breast and uterine disease: from
bench to treatment. Pharmacol Rev 2005, 57(3):359-383.
3. Irahara N, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S: Quantitative analysis
of aromatase mRNA expression derived from various promoters (I.4, I.3,
PII and I.7) and its association with expression of TNF-alpha, IL-6 and
COX-2 mRNAs in human breast cancer. Int J Cancer 2006,
118(8):1915-1921.
4. O’Neill JS, Elton RA, Miller WR: Aromatase activity in adipose tissue from
breast quadrants: a link with tumour site. Br Med J (Clin Res Ed) 1988,
296(6624):741-743.
5. Agarwal VR, Bulun SE, Leitch M, Rohrich R, Simpson ER: Use of alternative
promoters to express the aromatase cytochrome P450 (CYP19) gene in
breast adipose tissues of cancer-free and breast cancer patients. J Clin
Endocrinol Metab 1996, 81(11):3843-3849.
6. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL,
Shore RE, Strax P, Pasternack BS: A prospective study of endogenous
estrogens and breast cancer in postmenopausal women. J Natl Cancer
Inst 1995, 87(3):190-197.
7. Paridaens R, Thomas J, Wildiers J, Vermeiren P, Lobelle JP, di Salle E,
Ornati G, Zurlo MG, Polli A, Lanzalone S, et al: Safety, activity and estrogen
inhibition by exemestane in postmenopausal women with advanced
breast cancer: a phase I study. Anticancer Drugs 1998, 9(8):675-683.
8. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).: Effects of
chemotherapy and hormonal therapy for early breast cancer on
recurrence and 15-year survival: an overview of the randomised trials.
Lancet 2005, 365(9472):1687-1717.
Garcia-Casado et al. BMC Cancer 2010, 10:36
http://www.biomedcentral.com/1471-2407/10/36
Page 10 of 119. Smith IE, Dowsett M: Aromatase inhibitors in breast cancer. N Engl J Med
2003, 348(24):2431-2442.
10. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE: Influence of letrozole
and anastrozole on total body aromatization and plasma estrogen levels
in postmenopausal breast cancer patients evaluated in a randomized,
cross-over study. J Clin Oncol 2002, 20(3):751-757.
11. Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG,
Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A, Berstein LM: Phase 2
randomized trial of primary endocrine therapy versus chemotherapy in
postmenopausal patients with estrogen receptor-positive breast cancer.
Cancer 2007, 110(2):244-254.
12. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J,
Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, et al: Preoperative
treatment of postmenopausal breast cancer patients with letrozole: A
randomized double-blind multicenter study. Ann Oncol 2001,
12(11):1527-1532.
13. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F,
Miller WR, Evans DB, Dugan M, Brady C, et al: Letrozole is more effective
neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-
2-positive, estrogen receptor-positive primary breast cancer: evidence
from a phase III randomized trial. J Clin Oncol 2001, 19(18):3808-3816.
14. Smith I, Dowsett M, trialists oboI: Comparison of anastrozole vs tamoxifen
alone and in combination as neoadjuvant treatment of estrogen
receptor-positive (ER+) operable breast cancer in posmenopausal
women: The IMPACT trial. Breast Cancer Res Treat 2003, 82(suppl 2):S9-S15.
15. Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL,
Kelemen L, Ogata S, Pharoah PD, et al: Polymorphisms associated with
circulating sex hormone levels in postmenopausal women. J Natl Cancer
Inst 2004, 96(12):936-945.
16. Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y,
Stapleton PL, Lampe JW, Farin FM, et al: Association of CYP17, CYP19,
CYP1B1, and COMT polymorphisms with serum and urinary sex
hormone concentrations in postmenopausal women. Cancer Epidemiol
Biomarkers Prev 2004, 13(1):94-101.
17. Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G,
Thun MJ, Albanes D, Altshuler D, Ardanaz E, et al: Genetic variation at the
CYP19A1 locus predicts circulating estrogen levels but not breast cancer
risk in postmenopausal women. Cancer Res 2007, 67(5):1893-1897.
18. Ribeiro FS, de Amorim LM, de Almeida Simao T, Mendonca GA, de Moura
Gallo CV, Pinto LF: CYP19 (TTTA)n polymorphism and breast cancer risk
in Brazilian women. Toxicol Lett 2006, 164(1):90-95.
19. Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P, Borresen-
Dale AL: A rare CYP19 (aromatase) variant may increase the risk of
breast cancer. Pharmacogenetics 1998, 8(1):43-48.
20. Baxter SW, Choong DY, Eccles DM, Campbell IG: Polymorphic variation in
CYP19 and the risk of breast cancer. Carcinogenesis 2001, 22(2):347-349.
21. Probst-Hensch NM, Ingles SA, Diep AT, Haile RW, Stanczyk FZ, Kolonel LN,
Henderson BE: Aromatase and breast cancer susceptibility. Endocr Relat
Cancer 1999, 6(2):165-173.
22. Thyagarajan B, Brott M, Mink P, Folsom AR, Anderson KE, Oetting WS,
Gross M: CYP1B1 and CYP19 gene polymorphisms and breast cancer
incidence: no association in the ARIC study. Cancer Lett 2004,
207(2):183-189.
23. Ralph DA, Zhao LP, Aston CE, Manjeshwar S, Pugh TW, DeFreese DC,
Gramling BA, Shimasaki CD, Jupe ER: Age-specific association of steroid
hormone pathway gene polymorphisms with breast cancer risk. Cancer
2007, 109(10):1940-1948.
24. Olson JE, Ingle JN, Ma CX, Pelleymounter LL, Schaid DJ, Pankratz VS,
Vierkant RA, Fredericksen ZS, Wu Y, Couch FJ, et al: A comprehensive
examination of CYP19 variation and risk of breast cancer using two
haplotype-tagging approaches. Breast Cancer Res Treat 2007,
102(2):237-247.
25. Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B,
Karesen R, Kristensen T, Borresen-Dale AL: Genetic variants of CYP19
(aromatase) and breast cancer risk. Oncogene 2000, 19(10):1329-1333.
26. Haiman CA, Hankinson SE, Spiegelman D, Brown M, Hunter DJ: No
association between a single nucleotide polymorphism in CYP19 and
breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11(2):215-216.
27. Fasching PA, Loehberg CR, Strissel PL, Lux MP, Bani MR, Schrauder M,
Geiler S, Ringleff K, Oeser S, Weihbrecht S, et al: Single nucleotide
polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and
prognosis in breast cancer patients. Breast Cancer Res Treat 2008,
112(1):89-98.
28. Long JR, Kataoka N, Shu XO, Wen W, Gao YT, Cai Q, Zheng W: Genetic
polymorphisms of the CYP19A1 gene and breast cancer survival. Cancer
Epidemiol Biomarkers Prev 2006, 15(11):2115-2122.
29. Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A, Calvo L,
Carabantes F, Crespo C, Munoz M, et al: A single-nucleotide
polymorphism in the aromatase gene is associated with the efficacy of
the aromatase inhibitor letrozole in advanced breast carcinoma. Clin
Cancer Res 2008, 14(3):811-816.
30. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The
value of histological grade in breast cancer: experience from a large
study with long-term follow-up. . Histopathology 2002, 41(3A):151,
Comment on C. W. Elston 19; 403-410.
31. Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S,
Everett T, Harpole D, Moore MB, Berry DA, et al: Comparison of methods
of measuring HER-2 in metastatic breast cancer patients treated with
high-dose chemotherapy. J Clin Oncol 2001, 19(6):1698-1706.
32. Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L,
Eckloff BW, Schaid D, Wieben ED, Adjei AA, et al: Human aromatase: gene
resequencing and functional genomics. Cancer Res 2005,
65(23):11071-11082.
33. Stern C: The Hardy-Weinberg Law. Science 1943, 97(2510):137-138.
34. Kaplan E, Meier P: Nonparametric estimation from incomplete
observations. J Am Stat Assoc 1958, 53:457-481.
35. Peto R, Peto P: Asymptomatically efficient rank invariant test procedures.
J Roy Stat Soc 1987, 135:185-206.
36. Cox D: Regression models and life tables. J R Stat Soc 1972, 34:187-220.
37. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer
treatment. Cancer 1981, 47(1):207-214.
38. Dowsett M, Martin LA, Smith I, Johnston S: Mechanisms of resistance to
aromatase inhibitors. J Steroid Biochem Mol Biol 2005, 95(1-5):167-172.
39. Punglia RS, Burstein HJ, Winer EP, Weeks JC: Pharmacogenomic variation
of CYP2D6 and the choice of optimal adjuvant endocrine therapy for
postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst
2008, 100(9):642-648.
40. Bulun SE, Takayama K, Suzuki T, Sasano H, Yilmaz B, Sebastian S:
Organization of the human aromatase p450 (CYP19) gene. Seminars in
reproductive medicine 2004, 22(1):5-9.
41. Rhiem K, Klein A, Munch M, Kreutzfeld R, Ramser J, Wardelmann E,
Schackert G, Von Deimling A, Wiestler OD, Schmutzler RK: Chromosomal
region 15q21.1 is a frequent target of allelic imbalance in advanced
breast carcinomas. Int J Cancer 2003, 106(1):74-77.
42. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J,
Detre S, Hills M, Ashley S, et al: Biomarker changes during neoadjuvant
anastrozole, tamoxifen, or the combination: influence of hormonal
status and HER-2 in breast cancer–a study from the IMPACT trialists. J
Clin Oncol 2005, 23(11):2477-2492.
43. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A,
Drury S, Larionov A, Young O, White S, et al: Molecular response to
aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res
2007, 9(3):R37.
Pre-publication history
The pre-publication history for this paper can be accessed here:http://www.
biomedcentral.com/1471-2407/10/36/prepub
doi:10.1186/1471-2407-10-36
Cite this article as: Garcia-Casado et al.: A polymorphism at the 3’-UTR
region of the aromatase gene defines a subgroup of postmenopausal
breast cancer patients with poor response to neoadjuvant letrozole.
BMC Cancer 2010 10:36.
Garcia-Casado et al. BMC Cancer 2010, 10:36
http://www.biomedcentral.com/1471-2407/10/36
Page 11 of 11